Department of Immunohematology and Blood Transfusion, Leiden University Medical Center Leiden, Netherlands.
Front Immunol. 2013 May 14;4:113. doi: 10.3389/fimmu.2013.00113. eCollection 2013.
Tolerogenic dendritic cells (DCs) work through silencing of differentiated antigen-specific T cells, activation and expansion of naturally occurring T regulatory cells (Tregs), transfer of regulatory properties to T cells, and the differentiation of naïve T cells into Tregs. Due to an operational definition based on T cell activation assays, the identity of tolerogenic DCs has been a matter of debate and it need not represent a specialized DC subset. Human tolerogenic DCs generated in vitro using inhibitory cytokines, growth factors, natural immunomodulators, or genetic manipulation have been effective and several of these tolerogenic DCs are currently being tested for clinical use. Ex vivo generated tolerogenic DCs reduce activation of naïve T cells using various means, promote a variety of regulatory T cells and most importantly, frequently show stable inhibitory phenotypes upon repetitive maturation with inflammatory factors. Yet, tolerogenic DCs differ with respect to the phenotype or the number of regulatory mechanisms they employ to modulate the immune system. In our experience, tolerogenic DCs generated using the biologically active form of vitamin D (VD3-DCs), alone, or combined with dexamethasone are proficient in their immunoregulatory functions. These tolerogenic DCs show a stable maturation-resistant semi-mature phenotype with low expression of activating co-stimulatory molecules, no production of the IL-12 family of cytokines and high expression of inhibitory molecules and IL-10. VD3-DCs induce increased apoptosis of effector T cells and induce antigen-specific regulatory T cells, which work through linked suppression ensuring infectious tolerance. Lessons learned on VD3-DCs help understanding the contribution of different pattern-recognition receptors (PRRs) and secondary signals to the tolerogenic function and how a cross-talk between DCs and T cells translates into immune regulation.
耐受性树突状细胞(DC)通过沉默分化的抗原特异性 T 细胞、激活和扩增天然存在的调节性 T 细胞(Treg)、将调节性表型转移至 T 细胞、以及将初始 T 细胞分化为 Treg 来发挥作用。由于基于 T 细胞激活测定的操作定义,耐受性 DC 的身份一直存在争议,并且它不一定代表一种专门的 DC 亚群。使用抑制性细胞因子、生长因子、天然免疫调节剂或遗传操作在体外生成的人源耐受性 DC 已被证明有效,其中一些耐受性 DC 目前正在进行临床试验。体外生成的耐受性 DC 通过各种手段减少初始 T 细胞的激活,促进多种调节性 T 细胞的产生,最重要的是,在与炎症因子反复成熟后,通常表现出稳定的抑制表型。然而,耐受性 DC 在其用于调节免疫系统的表型或调节机制的数量上存在差异。根据我们的经验,使用生物活性形式的维生素 D(VD3-DC)单独或与地塞米松联合生成的耐受性 DC 在其免疫调节功能方面表现出色。这些耐受性 DC 表现出稳定的成熟抵抗的半成熟表型,其激活共刺激分子表达水平低、不产生 IL-12 细胞因子家族、高表达抑制分子和 IL-10。VD3-DC 诱导效应 T 细胞凋亡增加,并诱导抗原特异性调节性 T 细胞,通过连锁抑制作用确保感染性耐受。在 VD3-DC 上获得的经验教训有助于理解不同模式识别受体(PRR)和二级信号对耐受性功能的贡献,以及 DC 和 T 细胞之间的串扰如何转化为免疫调节。